Efficacy and durability of therapies for neurogenic lower urinary tract dysfunction: A network meta-analysis of Botulinum Toxin a, instillations, and neuromodulation.
Beibei Lei, Cunyu Lan, Yage Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated the efficacy and durability of botulinum toxin A (BTA), instillations, and neuromodulation for neurogenic lower urinary tract dysfunction (NLUTD) in 3779 participants across 25 RCTs. Abo-BTA 600U showed the greatest short-term increase in maximum cystometric capacity (MCC) with a mean difference of 174.57. Long-term, Abo-BTA 750U maintained effectiveness, indicating a potential for sustained therapeutic benefit.
Key findings
- Abo-BTA 600U showed a mean difference of 174.57 in maximum cystometric capacity (MCC).
- Abo-BTA 800U resulted in a short-term reduction of incontinence episode frequency (IEF) by -14.32.
- Long-term efficacy was maintained only by Abo-BTA 750U, indicating time-dependent attenuation of benefits.
- Higher injection-site density may enhance treatment durability compared to other interventions.
Why it matters
Understanding the efficacy and durability of treatments for NLUTD is crucial for clinicians to optimize patient management. This analysis highlights the potential of specific BTA formulations to provide both immediate relief and sustained benefits, informing treatment decisions.